Abstract MP44: Plasma Proteomic Signature Of BMI Reveals Heterogeneous Cardiometabolic Risk Profiles Within And Across Standard BMI Classifications — Kevin B. Jacobs (2025) | RDL Network
Abstract MP44: Plasma Proteomic Signature Of BMI Reveals Heterogeneous Cardiometabolic Risk Profiles Within And Across Standard BMI Classifications
Circulation 151(Suppl_1)
Article 2025 English
Authors
KJ
Kevin B. Jacobs
EL
Eric C. Leszczynski
JB
Jacob L. Barber
Abstract
1 min read
Background: The proteome is altered in obesity and proteomic signatures of BMI have been identified. However, few studies have examined differences in clinical profiles between actual and protein-predicted BMI. Hypothesis: Plasma protein-based BMI classification will better capture cardiometabolic risk compared to actual BMI classification. Methods: Data on cardiometabolic phenotypes and plasma proteins (4979 proteins via SomaScan) were available in 645 adults (56% Female, 35% Black, 17-65 yrs) from the HERITAGE Family Study. LASSO regression models with 10-fold-cross-validation were used to create a BMI proteomic signature. Protein-predicted BMI was classified into weight classes and compared to actual BMI classification to create 7 groups (underpredicted, matched, or overpredicted) ( Fig 1A ). General linear models adjusted for age, sex, race, and measured BMI were used to examine differences in cardiometabolic traits across groups. Results: The LASSO model (R 2 =0.82, RMSE=2.2) included 208 proteins. Protein-predicted BMI correlated with actual BMI at r=0.95 (p<0.0001), with a 16% misclassification rate ( Fig 1A ). Participants whose proteins underpredicted BMI class generally had more favorable cardiometabolic profiles than matched groups of the same class, while overpredicted BMI class groups showed worse cardiometabolic profiles than matched groups of the same class ( Fig 1B ). Conclusions: We identified individuals matched for BMI but with opposing proteomic signatures that differed in cardiometabolic risk profiles. Proteomic profiling may identify clinically meaningful heterogeneity in cardiometabolic health not fully captured by BMI that could potentially be used as biomarkers and/or targets of therapeutic responsiveness.
Eric C. Leszczynski, Prasun K Dev, Jacob L. Barber, Prashant Rao, Michael Mi, Sujoy Ghosh, Clary B. Clish, Claude Bouchard, Jeremy Robbins, Robert E. Gerszten, Mark A. Sarzynski
Qianyan Zheng, Zicheng Wang, Marta Guasch‐Ferré, Fenglei Wang, JoAnn E. Manson, Xiang Li, Qi Sun, Liming Liang, Zsu‐Zsu Chen, Robert E. Gerszten, Meir J. Stampfer, Walter C. Willett, Frank B Hu, A. Heather Eliassen, Danielle E. Haslam, Shilpa N. Bhupathiraju
Alexander Vanmaele, Jean‐Paul Mira, Sanne E. Hoeks, Elke Bouwens, K. Martijn Akkerhuis, Jorg de Bruin, Sander Ten Raa, Bram Fioole, Joost Daemen, Nicolas M. Van Mieghem, Robert van Geuns, Patrick W. Serruys, Hence J.M. Verhagen, Eric Boersma, Isabella Kardys
Matthew Herzig, Prasun K Dev, Kevin B. Jacobs, Eric C. Leszczynski, Jacob L. Barber, Prashant Rao, Michael Mi, Matthew Valakos, Sujoy Ghosh, Clary B. Clish, Claude Bouchard, Robert E. Gerszten, Jeremy Robbins, Mark A. Sarzynski
Discussion(0)
No comments yet. Be the first to comment.